Phase Ib, open-label study of add on therapy with CK0804 in participants with myelofibrosis, with suboptimal response to ruxolitinib.

CK0804 - Cellenkos, Incyte

Jakafi (ruxolitinib) - Novartis, Incyte

https://meetings.asco.org/abstracts-presentations/225986

Lucia Masarova; Meixian Huang; Tapan M. Kadia; Naveen Pemmaraju; Naval Guastad Daver; Mi-Ae Lyu; Ke Zeng; Tara Sadeghi; Ekatherine Asatiani; Simrit Parmar; Christopher Flowers; Srdan Verstovsek

Apr 27, 2023